TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT05675319

Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.
“The reason for the end of recruitment is that the recruitment target could not be achieved despite all efforts and the G-BA (financing party) does not consider a continuation of the AlloRelapseMM study to be expedient.”

The sponsor’s own words in the registry.

Life of this trial

20222023202420252026Registered2022-11-06Started2023-03-03Primary completion2025-03-14Stopped2025-03-21

Vital statistics

Status
Terminated
Phase
Phase 3
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Sponsor type
University, hospital or other
Conditions
Multiple Myeloma
Interventions
Allogeneic Stem Cells; carfilzomib/lenalidomide/dexamethasone (KRD); elotuzumab/lenalidomide/dexamethasone (ERD); daratumumab/bortezomib/dexamethasone (DVD); daratumumab/lenalidomide/dexamethasone (DRD); ixazomib/lenalidomide/dexamethasone (IRD)
Participants
28
Sites
30
Countries
Germany

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.